CRH and pancreatic neoplasm: There was one early report showing that this compound and its derivatives might be antagonists of corticotropin-releasing factor (CRF) receptor [43], but it is unlikely that blockade of the CRF receptor by NSC84167 is involved in its selective anticancer activity in pancreatic cancer, since ductal pancreatic cancers lack the CRF receptor [44].